PE20090279A1 - Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2 - Google Patents
Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2Info
- Publication number
- PE20090279A1 PE20090279A1 PE2008000842A PE2008000842A PE20090279A1 PE 20090279 A1 PE20090279 A1 PE 20090279A1 PE 2008000842 A PE2008000842 A PE 2008000842A PE 2008000842 A PE2008000842 A PE 2008000842A PE 20090279 A1 PE20090279 A1 PE 20090279A1
- Authority
- PE
- Peru
- Prior art keywords
- mdm2
- spyroindolinone
- derivatives
- diona
- octa
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 CYANE Chemical class 0.000 abstract 2
- USIHWOUIRZQNSJ-WHKRWAEBSA-N C/C=C(\C)/[C@@H](CNCC[C@H]1C2=CC(Cl)=CC=C2)[C@]1(CNC1=C2)C1=CC=C2Cl Chemical compound C/C=C(\C)/[C@@H](CNCC[C@H]1C2=CC(Cl)=CC=C2)[C@]1(CNC1=C2)C1=CC=C2Cl USIHWOUIRZQNSJ-WHKRWAEBSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical class [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE ESPIROINDOLINONA DE FORMULAS (Ia) Y (Ib), DONDE X ES H, HALOGENO, CIANO, NITRO, ETINILO Y CICLOPROPILO; Y ES H O F; R1, R2, R3 Y R4 SON H, ALQUILO, ALCOXILO, ALQUINILO, ENTRE OTROS; R5 ES H, ALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3R,4S,5S)-6'-CLORO-5-(3-CLOROFENIL)-1,1',2,2',3,5,6,7-OCTA-HIDRO-3-(1-METILETENILESPIRO[4H-AZEPINA-4,3'-[3H]-INDOL]-2',7-DIONA, (3R,4S,5S)-6'-CLORO-5-(3-CLOROFENIL)-1,1',2,2',3,5,6,7-OCTA-HIDRO-3(E)-(1-METIL-1-PROPENIL)-ESPIRO[4H-AZEPINA-4,3'-[3H]-INDOL]-2',7-DIONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LAS INTERACCIONES DE LA PROTEINA MDM2 Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS DE PROLIFERACION CELULAR, PARTICULARMENTE TRANSTORNOS ONCOLOGICOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93849407P | 2007-05-17 | 2007-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090279A1 true PE20090279A1 (es) | 2009-04-02 |
Family
ID=39645551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000842A PE20090279A1 (es) | 2007-05-17 | 2008-05-14 | Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7553833B2 (es) |
| EP (1) | EP2158205B1 (es) |
| JP (1) | JP2010527340A (es) |
| KR (1) | KR101162518B1 (es) |
| CN (1) | CN101679446B (es) |
| AR (1) | AR066583A1 (es) |
| AT (1) | ATE536355T1 (es) |
| AU (1) | AU2008253154A1 (es) |
| BR (1) | BRPI0811718A2 (es) |
| CA (1) | CA2686675A1 (es) |
| ES (1) | ES2377245T3 (es) |
| IL (1) | IL201973A0 (es) |
| MX (1) | MX2009012345A (es) |
| PE (1) | PE20090279A1 (es) |
| TW (1) | TW200906832A (es) |
| WO (1) | WO2008141917A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638548B2 (en) * | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7723372B2 (en) | 2008-03-19 | 2010-05-25 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US20100190814A1 (en) * | 2009-01-26 | 2010-07-29 | Li Chen | Spiroindolinone derivative prodrugs |
| US7928233B2 (en) * | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
| US8217051B2 (en) * | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| UA107814C2 (uk) * | 2009-11-12 | 2015-02-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи мdм2 |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8288431B2 (en) * | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| UA109464C2 (uk) | 2010-11-12 | 2015-08-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи mdm2 |
| PT2684880T (pt) | 2011-03-10 | 2018-04-27 | Daiichi Sankyo Co Ltd | Derivado de dispiropirrolidina |
| CA2835422C (en) | 2011-05-11 | 2016-10-11 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| CN103992334A (zh) * | 2014-05-29 | 2014-08-20 | 中国人民解放军第二军医大学 | 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法 |
| WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| LT3183254T (lt) | 2014-08-21 | 2019-08-26 | Boehringer Ingelheim International Gmbh | Naujieji spiro[3h-indol-3,2' -pirolidin]-2(1h)-ono junginiai ir dariniai, kaip mdm2-p53 inhibitoriai |
| WO2016133194A1 (ja) | 2015-02-20 | 2016-08-25 | 第一三共株式会社 | がんの併用治療法 |
| CN105541716B (zh) | 2015-03-26 | 2024-02-23 | Ａｇｃ株式会社 | 吡唑衍生物的制造方法 |
| EP3284466A4 (en) | 2015-04-13 | 2018-12-05 | Daiichi Sankyo Company, Limited | Treatment method combining mdm2 inhibitor and btk inhibitor |
| TWI737635B (zh) | 2015-10-09 | 2021-09-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為mdm2－p53抑制劑之新穎螺﹝3h－吲哚－3，2´－吡咯啶﹞－2（1h）－酮化合物及其衍生物 |
| CN109415336B (zh) | 2016-04-06 | 2023-08-29 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| JP7001614B2 (ja) | 2016-04-06 | 2022-02-03 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | リガンド依存性の標的タンパク質分解のための単官能性中間体 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| EP3527226A4 (en) | 2016-10-17 | 2020-06-17 | Daiichi Sankyo Company, Limited | Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor |
| CN107337638A (zh) * | 2017-08-14 | 2017-11-10 | 侯茜茜 | 一种吡啶甲酸类食品添加剂的高效合成方法 |
| KR20210072043A (ko) | 2018-10-08 | 2021-06-16 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 소분자 mdm 2 단백질 분해제 |
| IL296451A (en) | 2020-03-19 | 2022-11-01 | Kymera Therapeutics Inc | Mdm2 degraders and uses thereof |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN116496281B (zh) * | 2022-12-30 | 2025-05-13 | 重庆文理学院 | 一种苯并氮卓螺二氢吲哚化合物及其合成方法与应用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2098212B (en) * | 1981-05-12 | 1984-11-14 | Ici Plc | Process for preparing 1'-substituted-spiro(imidazolidine)-4,3'-indoline-2,2',5-triones |
| EP0947511A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
| MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| US20070213341A1 (en) * | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
-
2008
- 2008-04-11 US US12/101,182 patent/US7553833B2/en not_active Expired - Fee Related
- 2008-05-06 BR BRPI0811718-7A2A patent/BRPI0811718A2/pt not_active IP Right Cessation
- 2008-05-06 JP JP2010507884A patent/JP2010527340A/ja active Pending
- 2008-05-06 KR KR1020097023637A patent/KR101162518B1/ko not_active Expired - Fee Related
- 2008-05-06 AU AU2008253154A patent/AU2008253154A1/en not_active Abandoned
- 2008-05-06 MX MX2009012345A patent/MX2009012345A/es active IP Right Grant
- 2008-05-06 AT AT08750071T patent/ATE536355T1/de active
- 2008-05-06 ES ES08750071T patent/ES2377245T3/es active Active
- 2008-05-06 CA CA002686675A patent/CA2686675A1/en not_active Abandoned
- 2008-05-06 CN CN2008800164254A patent/CN101679446B/zh not_active Expired - Fee Related
- 2008-05-06 WO PCT/EP2008/055516 patent/WO2008141917A1/en not_active Ceased
- 2008-05-06 EP EP08750071A patent/EP2158205B1/en not_active Not-in-force
- 2008-05-14 TW TW097117735A patent/TW200906832A/zh unknown
- 2008-05-14 PE PE2008000842A patent/PE20090279A1/es not_active Application Discontinuation
- 2008-05-15 AR ARP080102062A patent/AR066583A1/es unknown
-
2009
- 2009-11-05 IL IL201973A patent/IL201973A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE536355T1 (de) | 2011-12-15 |
| KR101162518B1 (ko) | 2012-07-09 |
| MX2009012345A (es) | 2009-12-01 |
| US20080287421A1 (en) | 2008-11-20 |
| CN101679446B (zh) | 2012-06-27 |
| WO2008141917A1 (en) | 2008-11-27 |
| US7553833B2 (en) | 2009-06-30 |
| EP2158205A1 (en) | 2010-03-03 |
| EP2158205B1 (en) | 2011-12-07 |
| KR20090130312A (ko) | 2009-12-22 |
| BRPI0811718A2 (pt) | 2014-11-18 |
| CN101679446A (zh) | 2010-03-24 |
| AR066583A1 (es) | 2009-09-02 |
| TW200906832A (en) | 2009-02-16 |
| JP2010527340A (ja) | 2010-08-12 |
| AU2008253154A1 (en) | 2008-11-27 |
| ES2377245T3 (es) | 2012-03-23 |
| IL201973A0 (en) | 2010-06-16 |
| CA2686675A1 (en) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090279A1 (es) | Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2 | |
| PE20081346A1 (es) | Derivados de espiroindolinona como antagonistas de mdm2 | |
| PE20090718A1 (es) | Derivados de espiroindolinona | |
| PE20011066A1 (es) | PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS | |
| PE20060555A1 (es) | Derivados de pirrol-oxindol como moduladores del receptor de progesterona | |
| PE20040999A1 (es) | Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| PE20070108A1 (es) | Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n-[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| PE20041076A1 (es) | Nuevas pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina | |
| PE20080403A1 (es) | Derivados heterociclicos fusionados y metodos de uso | |
| PE20090229A1 (es) | DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53 | |
| PE20040165A1 (es) | Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular | |
| CO5700778A2 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
| PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
| PE20081377A1 (es) | Compuestos de tiazol pirazolopirimidina | |
| CL2008001946A1 (es) | Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas. | |
| PE20080704A1 (es) | Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
| PE20011305A1 (es) | Agentes diazabiciclicos activos en el snc | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| PE20040647A1 (es) | Inhibidores de cinasas de tirosina | |
| PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
| ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| PE20050679A1 (es) | Compuestos de pirrolotriazina como inhibidores de la cinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |